Patent application number | Description | Published |
20080292641 | Antigenic GM-CSF peptides and antibodies to GM-CSF - Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease. | 11-27-2008 |
20080318321 | Methods for Generating Hypermutable Microbes - Bacteria are manipulated to create desirable output traits using dominant negative alleles of mismatch repair proteins. Enhanced hypermutation is achieved by combination of mismatch repair deficiency and exogenously applied mutagens. Stable bacteria containing desirable output traits are obtained by restoring mismatch repair activity to the bacteria. | 12-25-2008 |
20090105453 | Interleukin-9 receptor mutants - This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma. | 04-23-2009 |
20090137427 | Method for generating hypermutable organisms - Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. The enhanced rate of mutation can be further augmented using mutagens. Moreover, the hypermutability of mismatch repair deficient cells can be remedied to stabilize cells or mammals with useful mutations. | 05-28-2009 |
20110055964 | Method for Generating Hypermutable Plants - Blockade of mismatch repair in a plant can lead to hypermutation and a new genotype and/or phenotype. One approach used to generate hypermutable plants is through the expression of dominant negative alleles of mismatch repair genes in transgenic plants or derived cells. By introducing these genes into cells and transgenic plants, new cell lines and plant varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. Moreover, methods to inhibit the expression and activity of endogenous plant MMR genes and their encoded products are also useful to generate hypermutable plants. | 03-03-2011 |
20110224406 | INTERLEUKIN-9 RECEPTOR MUTANTS - This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma. | 09-15-2011 |
20120171223 | HIGH AFFINITY ANTIBODIES THAT NEUTRALIZE STAPHYLOCOCCUS ENTEROTOXIN B - This invention provides antibodies that specifically bind and neutralize | 07-05-2012 |
20130058945 | Antigenic GM-CSF Peptides and Antibodies to GM-CSF - Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease. | 03-07-2013 |
20130183314 | HIGH AFFINITY ANTIBODIES THAT NEUTRALIZE STAPHYLOCOCCUS ENTEROTOXIN B - This invention provides antibodies that specifically bind and neutralize | 07-18-2013 |
20140072553 | High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B - Provided herein are antibodies that specifically bind and neutralize | 03-13-2014 |
20150050276 | High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B - Provided herein are antibodies that specifically bind and neutralize | 02-19-2015 |